Ferroptosis-related alternative splicing signatures as potential biomarkers for predicting prognosis and therapy response in gastric cancer
Gang Long,
Zhiyong Li,
Yue Gao,
Xu Zhang,
Xiyang Cheng,
Irankunda Eric Daniel,
Lisha Zhang,
Dawei Wang,
Zhengtian Li
Affiliations
Gang Long
Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, No.23 Post Street, Nangang district, Harbin, 150007, China
Zhiyong Li
Department of General Surgery, Peking University People's Hospital, Beijing, 100044, China
Yue Gao
Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, No.23 Post Street, Nangang district, Harbin, 150007, China
Xu Zhang
Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, No.23 Post Street, Nangang district, Harbin, 150007, China
Xiyang Cheng
Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, No.23 Post Street, Nangang district, Harbin, 150007, China
Irankunda Eric Daniel
Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, No.23 Post Street, Nangang district, Harbin, 150007, China
Lisha Zhang
Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, No.23 Post Street, Nangang district, Harbin, 150007, China
Dawei Wang
Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, No.23 Post Street, Nangang district, Harbin, 150007, China
Zhengtian Li
Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, No.23 Post Street, Nangang district, Harbin, 150007, China; Corresponding author.
Ferroptosis is linked to various tumor biological traits, and alternative splicing (AS), a crucial step in mRNA processing, plays a role in the post-transcriptional regulation of ferroptosis-related genes (FRGs). A least absolute shrinkage and selection operator (LASSO) penalized Cox regression analysis was utilized to build a prognostic signature based on 12 AS events (p 0.4, FDR<0.05). Furthermore, our functional assay results suggested that high SF3A2 expression might increase ferroptosis resistance and promote cell proliferation. In conclusion, the FRAs model we built has an advantage in predicting GC prognosis. The model's demonstration of variations in the immune microenvironment and drug response could potentially inform decisions regarding treatment strategies.
